CRISPR Therapeutics
Develops genome-editing medicines across blood disorders, liver targets, autoimmune disease, and diabetes.
Something off on this page? Send us feedback.
Profile
Develops CRISPR-based medicines for blood disorders alongside in vivo editing, allogeneic CAR T, siRNA, and regenerative-medicine programs. CASGEVY is the approved commercial anchor; Vertex controls its global development, manufacturing, and commercialization under a profit-and-cost-sharing collaboration.
Develops gene-based medicines through CRISPR/Cas9 editing and related technologies. CASGEVY, an ex vivo edited-cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, is the approved commercial product and is partnered with Vertex.
The pipeline spans liver-directed in vivo editing through CTX310, CTX340, and CTX460; zugo-cel, an allogeneic CAR T candidate for autoimmune disease and blood cancers; CTX611, an siRNA candidate for clotting disorders; and CTX213, a beta-cell replacement candidate for diabetes. Lipid-nanoparticle delivery, SyNTase editing, and an internal cell-therapy manufacturing facility support these programs.
Operates as a single genome-editing therapeutics segment, with headquarters in Switzerland and research operations in the United States. Clinical progress depends on regulatory review, complex manufacturing, and intellectual-property rights. Vertex controls global development, manufacturing, and commercialization of CASGEVY under the collaboration agreement.
Company facts
Key statistics
Year to date +7.3% · Average volume (30d) 1.6M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 6, 2026 | Goldman Sachs | Reiterate | Neutral | $55 | |
| Jul 8, 2026 | H.C. Wainwright | Reiterate | Buy | $65 | $80 |
| Jun 12, 2026 | UBS | Target | $80 | ||
| Jun 11, 2026 | Morgan Stanley | Target | $33 | $60 | |
| May 13, 2026 | Bernstein | Reiterate | Market Perform | $56 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026Q2 FY26 | −$1.19 | −$0.94 | +21.0% | $7.4M | $10.2M | +36.7% | +7.06% |
| May 4, 2026Q1 FY26 | −$1.18 | −$1.28 | −8.2% | $6.1M | $1.5M | −76.0% | −2.24% |
| Feb 12, 2026Q4 FY25 | −$1.15 | −$1.37 | −19.1% | $4.7M | $864.0K | −81.7% | +8.46% |
| Nov 10, 2025Q3 FY25 | −$1.26 | −$1.17 | +7.1% | $9.1M | $889.0K | −90.3% | +1.15% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $865.0K | $892.0K | $889.0K | $864.0K | $1.5M | $10.2M | |
| Gross profit | −$56.6M | −$48.9M | −$63.8M | −$58.5M | −$48.8M | −$34.4M | |
| Operating income | −$148.4M | −$133.1M | −$132.1M | −$154.8M | −$130.2M | −$114.8M | |
| Net income | −$136.0M | −$208.5M | −$106.4M | −$130.6M | −$122.9M | −$91.2M | |
| Diluted EPS | −$1.58 | −$2.40 | −$1.17 | −$1.37 | −$1.28 | −$0.94 | |
| Gross margin | -6,548.4% | -5,477.7% | -7,177.1% | -6,770.8% | -3,346.4% | -337.8% | |
| Operating margin | -17,158.8% | -14,918.3% | -14,854.8% | -17,912.5% | -8,933.3% | -1,127.6% |
Fiscal years (4-quarter sums)FY21 $913.6M · FY22 $436.0K · FY23 $370.0M · FY24 $36.6M · FY25 $3.5M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $2.36B · Total debt $783.7M · Total assets $2.65B · Shareholders' equity $1.75B
Dividends
No dividends on record.
Ownership
Shares outstanding 96.45M · Float 96.04M · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ark Investment Management LLC | 9.46M | 9.81% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 8.35M | 8.66% | 13F | Aug 7, 2026 |
| Orbis Investment Management Ltd | 6.09M | 6.30% | 13G | May 15, 2026 |
| Orbis Allan Gray Ltd | 5.45M | 5.65% | 13F | Aug 14, 2026 |
| Capital World Investors | 4.75M | 4.92% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 29, 2026 | Naimish Patel | officer: Chief Medical Officer | −3,786 | $55.62 |
| Mar 23, 2026 | Raju Prasad | officer: Chief Financial Officer | −3,708 | $46.78 |
| Mar 23, 2026 | Samarth Kulkarni | director, officer: Chief Executive Officer | −10,020 | $46.78 |
| Mar 23, 2026 | James R. Kasinger | officer: General Counsel and Secretary | −3,182 | $46.78 |
| Mar 16, 2026 | Samarth Kulkarni | director, officer: Chief Executive Officer | −10,349 | $48.26 |
Peers
- Beam Therapeutics
Base-editing rival in SCD and liver genetic disease
- Intellia Therapeutics
Late-stage systemic CRISPR rival in in vivo editing
- Editas Medicine
CRISPR peer in hemoglobinopathy and in vivo editing
- Allogene Therapeutics
Off-the-shelf CAR T rival in oncology and autoimmunity
- Caribou Biosciences
CRISPR-edited allogeneic CAR T rival in blood cancers
- Fate
iPSC off-the-shelf CAR T rival in autoimmune disease
- Sana Biotechnology
Engineered islet-cell rival in regenerative medicine
- Prime Medicine
Prime-editing platform peer in liver and cell therapy
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Beam Therapeutics | $29.32 | +0.10% | $3.02B | — | — | 19.3 | −94.2% |
| Intellia Therapeutics | $12.87 | −0.01% | $1.80B | — | — | 30.2 | −46.2% |
| Editas Medicine | $3.14 | −0.30% | $484.9M | — | — | 10.3 | +232.3% |
| Allogene Therapeutics | $2.01 | −0.09% | $697.2M | — | — | 150.3 | — |
| Caribou Biosciences | $1.65 | +2.17% | $160.7M | — | — | 16.0 | −43.8% |
| Fate | $2.43 | +0.60% | $283.2M | — | — | 43.6 | +9.2% |
| Sana Biotechnology | $3.95 | +0.51% | $1.09B | — | — | — | — |
| Prime Medicine | $3.59 | −0.61% | $652.0M | — | — | 160.1 | +3.5% |
| Median | — | — | 30.2 | −20.1% |